{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000094","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.015954+00:00","generated_at":"2026-06-13T05:40:07.000054+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design","bullets":["Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.","Warrants exercisable at $2.04/share, immediately exercisable, expire July 24, 2028.","Net proceeds to fund seralutinib development/commercialization and working capital.","Participation from NEA, EcoR1, Armistice, Farallon, Madison Avenue Partners, and others.","Interim TORREY OLE data and PROSERA Phase 3 design disclosed via separate 8-K; conference call July 25."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000094","json":"https://secwatch.observer/filing/0001728117-23-000094.json","markdown":"https://secwatch.observer/filing/0001728117-23-000094.md","text":"https://secwatch.observer/filing/0001728117-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/0001728117-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/goss-20230719.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:40:07.000054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfe2a7ac3db4f047c94a2bd1c7a30c849ffc6955","claim":"Gossamer Bio, Inc. entered into Purchase Agreement with purchasers named therein, including certain directors and executive officers of the Company valued at approximately $212.1 million (effective 2023-07-19).","evidence_excerpt":"On July 19, 2023, Gossamer Bio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein, including certain directors and executive officers of the Company (the “Purchasers”), for the private placement (the “Private Placement”) of 129,869,440 shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/0001728117-23-000094-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"purchasers named therein, including certain directors and executive officers of the Company"},{"label":"Value","value":"approximately $212.1 million"},{"label":"Effective","value":"2023-07-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}